Talphera, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLPH research report →
Companytalphera.com
Talphera, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
- CEO
- Vincent J. Angotti
- IPO
- 2011
- Employees
- 13
- HQ
- San Mateo, CA, US
Price Chart
Valuation
- Market Cap
- $16.91M
- P/E
- -2.45
- P/S
- 16905.69
- P/B
- 1.89
- EV/EBITDA
- -0.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1451600.00%
- Net Margin
- -1425300.00%
- ROE
- -92.98%
- ROIC
- -55.55%
Growth & Income
- Revenue
- $28.00K · 0.00%
- Net Income
- $-14,290,000 · -9.89%
- EPS
- $-0.34 · 32.00%
- Op Income
- $-13,484,000
- FCF YoY
- 10.40%
Performance & Tape
- 52W High
- $1.57
- 52W Low
- $0.38
- 50D MA
- $0.81
- 200D MA
- $0.94
- Beta
- 0.79
- Avg Volume
- 195.10K
Get TickerSpark's AI analysis on TLPH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Angotti Vincent J. | other | 9,938 |
| Apr 2, 26 | ASADORIAN RAFFI | other | 2,444 |
| Apr 2, 26 | Aslam Shakil | other | 2,118 |
| Apr 2, 26 | Dasu Badri N | other | 2,444 |
| Mar 13, 26 | Angotti Vincent J. | buy | 213,310 |
| Mar 13, 26 | Nantahala Capital Management, LLC | other | 4,266,211 |
| Feb 12, 26 | Angotti Vincent J. | other | 594,000 |
| Feb 12, 26 | Angotti Vincent J. | buy | 105,364 |
| Feb 14, 26 | Angotti Vincent J. | other | 9,559 |
| Feb 10, 26 | Angotti Vincent J. | other | 3,179 |
Our TLPH Coverage
We haven't published any research on TLPH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TLPH Report →